Development and Characterization of Efficient Cell Culture Systems for Genotype 1 Hepatitis E Virus and Its Infectious cDNA Clone

Viruses. 2023 Mar 26;15(4):845. doi: 10.3390/v15040845.

Abstract

Hepatitis E virus (HEV) is a major cause of acute viral hepatitis globally. Genotype 1 HEV (HEV-1) is responsible for multiple outbreaks in developing countries, causing high mortality rates in pregnant women. However, studies on HEV-1 have been hindered by its poor replication in cultured cells. The JE04-1601S strain recovered from a Japanese patient with fulminant hepatitis E who contracted HEV-1 while traveling to India was serially passaged 12 times in human cell lines. The cell-culture-generated viruses (passage 12; p12) grew efficiently in human cell lines, but the replication was not fully supported in porcine cells. A full-length cDNA clone was constructed using JE04-1601S_p12 as a template. It was able to produce an infectious virus, and viral protein expression was detectable in the transfected PLC/PRF/5 cells and culture supernatants. Consistently, HEV-1 growth was also not fully supported in the cell culture of cDNA-derived JE04-1601S_p12 progenies, potentially recapitulating the narrow tropism of HEV-1 observed in vivo. The availability of an efficient cell culture system for HEV-1 and its infectious cDNA clone will be useful for studying HEV species tropism and mechanisms underlying severe hepatitis in HEV-1-infected pregnant women as well as for discovering and developing safer treatment options for this condition.

Keywords: cell culture system; genotype 1; hepatitis E virus; infectious cDNA clone; replication efficiency; serial passages; species tropism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Culture Techniques
  • Clone Cells
  • Communicable Diseases*
  • DNA, Complementary / genetics
  • Female
  • Genotype
  • Hepatitis E virus* / genetics
  • Hepatitis E*
  • Humans
  • Pregnancy
  • Swine
  • Virus Replication

Substances

  • DNA, Complementary

Grants and funding

This work was supported in part by the Research Program on Hepatitis from the Japan Agency for Medical Research and Development, AMED (to H.O., JP22fk0210075).